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Cytomegaloviruses (CMVs) are highly prevalent, persistent human pathogens that not
only evade but also shape our immune responses. Natural killer (NK) cells play an impor-
tant role in the control of CMV and CMVs have in turn developed a plethora of immuno-
evasion mechanisms targeting NK cells. This complex interplay can leave a long-lasting
imprint on the immune system in general and affect responses toward other pathogens
and vaccines. This review aims to provide an overview of NK cell biology and develop-
ment, the manipulation of NK cells by CMVs and the potential impact of these evasion
strategies on responses to vaccination.
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Introduction
Cytomegaloviruses (CMVs) are beta-herpesviruses that establish
life-long persistent infection of their hosts. After resolution of acute
infection, the virus enters a state of latency during which very few
genes are transcribed and no new viral progeny are being gen-
erated. Latency is interrupted by occasional reactivations of the
virus and expression of genes associated with the lytic virus life-
cycle [1]. The success of CMVs as pathogens is a consequence
of multiple immunoevasion mechanisms such as downregulation
of immunoreceptor ligands or expression of decoy molecules that
they employ against every arm of the immune system, including
NK cells, which play an important role in the early control of virally
infected and malignant cells [2]. Individuals lacking NK cells may
suffer from recurrent virus infections, most commonly caused by
herpes viruses and papilloma viruses, as well as increased sus-
ceptibility to malignant tumors [3–5]. However, in other cases,
there is no obvious clinical immunodeficiency associated with the
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absence of NK cells, indicating redundancy with other immune
compartments for distinct genetic deficiencies [6, 7]. As NK cells
also regulate other arms of the immune response, their modula-
tion by CMV can have broader consequences for immunity [8].
For instance, the strength of the primary NK cell response against
the virus can have a significant impact on the adaptive immune
response, although the underlying mechanisms for this are not
yet clear and vary according to host and virus genotypes [9, 10].
CMV infection is associated with expansion of effector memory
CD8 T cell clones that are sustained for the lifetime of the host
and can comprise a significant percentage of the total CD8 T cell
population in aging individuals [11]. Multiple lines of evidence
in experimental animals and in humans which will be discussed
in this review, now indicate that CMV infection leaves a similar
long-lasting imprint on NK cell phenotype and function, affecting
NK cell responses to other pathogens and to vaccination.
Vaccines facilitate control and eradication of infectious dis-
eases that have plagued humanity for centuries but new infections,
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including those with pandemic potential, continue to emerge.
Understanding the different factors that can influence the response
to vaccination is crucial for developing effective vaccines against
these new threats. Recent evidence suggests that NK cells can
contribute to both the induction and the effector phases of
vaccination-induced immunity but that this is dependent upon
the CMV-infection status of the vaccinated individual. Here we
provide an overview of NK cell biology and development, the
manipulation of NK cells by CMVs and the potential impact of
CMV evasion strategies on responses to vaccination.
NK cell activity depends on a balance
of signals from inhibitory and activating
receptors
As first-responders among lymphocytes, NK cells must be able to
react quickly to a wide variety of stimuli. They do not possess
a single specific antigen receptor but, rather, they express multi-
ple receptors and co-receptors that, synergistically, allow them to
recognize potential threats and coordinate responses with other
immune cells. Whether an NK cell will attack or tolerate a tumor
cell or an infected target cell depends on the net balance of sig-
nals transduced by this plethora of receptors. If activating signals
prevail, NK cell can kill the offending cell by lysis or induction of
apoptosis and/or can secrete cytokines and chemokines to activate
other arms of the immune system [12].
All NK cell receptors are germline-encoded and are often
present as co-receptors on other immune cells. Some of these
receptors, as well as their ligands, are stochastically expressed
which results in heterogeneity in the number and type of recep-
tors expressed by each NK cell within an individual. For example,
it has recently been estimated that individual humans may pos-
sess between 6000 and 35 000 phenotypically distinct NK cell sub-
sets [13]. Moreover, in some cases both receptors and their ligands
are encoded by polygenic loci with a high degree of polymorphism
in the population that leads to differences in susceptibility of hosts
to infection [14].
Inhibitory NK cell receptors recognize self-molecules that are
expressed on healthy cells and as such are responsible for the
prevention of autoimmune responses, especially in the context
of inflammation. These receptors also play a role in NK cell
education and threshold-setting for future activation (reviewed
in [15]). Downregulation of self-molecules can result in absence of
inhibitory signals and may lead to “missing-self” recognition [16].
MHC Class I molecules (HLA Class I in humans) are the principal
family of self-molecules recognised by inhibitory and activating
NK cell receptors [16–18].
In humans, there are three different families of NK cell recep-
tors for MHC I: Leukocyte Ig-like Receptor (LIR-1), CD94/NKG2
receptors and Killer-cell Immunoglobulin-like Receptors (KIRs).
LIR-1 is an inhibitory receptor and recognizes all major groups
of MHC Class I, although with varying specificities. CD94/NKG2
receptors can be activating (e.g. CD94/NKG2C) or inhibitory (e.g.
NKG2A) but recognize only HLA-E, whereas, activating (short-
tailed) and inhibitory (long-tailed) KIRs recognize all classical
Class I HLA molecules (A, B and C) but in an allele-specific,
and in some cases, peptide-selective manner (reviewed in [19]).
In addition, there are numerous non-MHC Class I ligands for
NK cells including the Clr/Ocil ligands that are recognized by
inhibitory NKR-PI C-type lectin receptors [20], nectins and nectin-
like molecules that are recognized by the activating receptor
DNAM-1, inhibitory TIGIT and CD96 that has so far been reported
to display both inhibitory (in mouse models) and activating prop-
erties [21–24]. Finally, ligands for activating NK cell receptors
can include self and altered-self molecules (including MHC-I-
bound peptides); induced self-ligands; foreign, virally encoded
molecules; and immune complexes (immunoglobulin Fc binding
to CD16) (reviewed in [15, 25]). Whilst such a wide arsenal of
inhibitory and activating NK cell receptors might seem redundant,
evolution of diverse receptor-mediated pathways is likely to have
been driven by pathogens, including cytomegaloviruses, which
have developed mechanisms to interfere with nearly all of these
pathways.
Cytomegalovirus-encoded immunoevasins
drive host evolution
Cytomegalovirus (CMV) immune evasion strategies target multi-
ple mechanisms in every arm of the immune response, permitting
successful dissemination through the population and establish-
ment of life-long, persistent infection. Human cytomegalovirus
(HCMV) infects a major portion of the world’s population [26]
however due to strict species specificity it cannot be used to infect
experimental animals. A number of closely related animal CMVs
exist that are used as models; the best established and most widely
used is murine CMV (MCMV) [27] due to the availability of numer-
ous mutant mouse and virus strains. Rhesus CMV is highly related
to HCMV and shares many gene families, however it is highly
prevalent in both wild and captive rhesus monkeys making it diffi-
cult and expensive to maintain seronegative animals. Additionally,
rhesus monkeys are much more expensive than mice and there are
significantly fewer monkey strains available [28]. Finally, CMVs
on their own represent excellent model organisms and tools for
manipulating the immune system due to the features discussed
below.
CMVs modulate NK cell responses by engaging inhibitory and
avoiding activating receptors using multiple and often polyfunc-
tional immunoevasins with wide specificities for numerous, often
unrelated, targets. Decoy molecules encoded by CMVs preserve
cell surface expression of inhibitory ligands whilst engagement of
activating receptors is avoided by downregulation of their ligands.
Additionally, CMVs encode Fc receptors that interfere with NK-
mediated antibody-dependent cell-mediated cytotoxicity(ADCC)
and complement attack [29]. The plethora of HCMV and MCMV
NK evasins is summarized in Table 1; details and mechanisms of
their action are beyond the scope of this review but can be found
elsewhere [9, 29–33].
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One of the best-described CMV decoy molecules is the MCMV-
encoded MHC I-like molecule, m157. Depending on the virus and
mouse strain, m157 can engage inhibitory Ly49I and C recep-
tors [34–36] and the activating Ly49H receptor [37, 38]. It has
been proposed that inhibitory Ly49 and KIR receptors predate acti-
vating counterparts [39] so it is possible that m157 evolved orig-
inally as an inhibitory Ly49 receptor decoy but virus-associated
mortality subsequently drove evolution of the activating Ly49H
receptor [31]. However, m157 has only a modest effect on NK cell
function in vivo and only in C57BL/6-related mouse strains and
it has recently been reported that wild mouse populations lacking
Ly49H thrive despite the high prevalence of MCMV infection in
the wild [40]. Inhibitory Ly49C is usually engaged in cis interac-
tions with MHC I on NK cells. In cis interactions the receptor is
interacting with its ligand present on the same cell and not on
the target cell (trans interaction). If a receptor is engaged in cis
it is not available for exploitation by m157 expressed in trans. It
appears that viral evasion has “selected” inhibitory receptors that
can ensure proper NK cell education and functionality in the pres-
ence of decoys by engaging in cis [35, 36, 41] (for review on cis
and trans interactions of cell surface receptors see [42]). Similarly,
the HCMV-encoded decoy molecule UL18 engages the inhibitory
receptor LIR-1 but the availability of LIR-1 is regulated by its cis
interactions with HLA molecules [43].
MHC I molecules are very efficiently downregulated during
both HCMV and MCMV infection in an effort to avoid presentation
of virally encoded peptides to CD8 T cells. As MHC Class I down-
regulation could lead to “missing-self” recognition and NK cell-
mediated killing of infected cells, CMVs have developed strategies
to either selectively downregulate MHC I molecules that are effi-
cient presenters of peptide to CD8 T cells, while sparing those that
are better at engaging inhibitory NK cell receptors (HCMV) [32],
or return some MHC I to the cell surface (MCMV) [30]. More-
over, HCMV stabilizes the expression of HLA-E, a ligand for the
inhibitory CD94/NKG2A receptor, by providing a mimetic-peptide
that overcomes inhibition of peptide loading [32, 44]. However,
HLA-E in HCMV infected individuals is also recognized by the acti-
vating receptor CD94/NKG2C, although the specificity is much
lower and co-engagement of NKG2A and NKG2C still results in
inhibition of NK cell [45]. Nevertheless, the evolutionary pres-
sure exerted by this recognition is sufficient to select for HCMV
strains with polymorphisms that abrogate recognition by NKG2C
but not NKG2A [46], at least in transplant patients. The impact
of these polymorphisms on the expansion of CD94/NKG2C+ NK
cells during HCMV infection is not yet known.
Missing self-recognition can also be mediated by non-MHC I
molecules; one such example is the MCMV-encoded decoy m12
that targets the inhibitory NKR-P1B receptor [47–49], and is
assumed to have driven the evolution of the related activating
receptor, NKR-P1C (NK1.1), that also recognizes m12 in a mouse-
and virus strain-dependent manner [50]. The SLAM family of
receptors (SFR) has also been shown to aid in MHC-I-dependent
missing-self recognition [51]. The ongoing evolutionary arms race
between viral immunoevasins and host defenses is also evident in
the evasion of activating receptor NKG2D, with CMVs encoding
multiple strategies to prevent surface expression of NKG2D ligands
(Table 1). Finally, in silicomodels show that CMV-like viruses that
modulate NK cell ligands and downregulate MHC I, can select for
genetically diverse and highly allele-specific receptor families with
activating and inhibitory members, such as KIR and Ly49 [52–55].
Influence of CMV on NK cell education
Binding of self-molecules via inhibitory receptors is also required
for NK cell education and modulation of effector function. Since
NK cell inhibitory receptors and their ligands are encoded by dis-
tinct loci located on different chromosomes, it is possible for some
NK cells to express inhibitory NK cell receptors for which there is
no self-ligand. Potential autoreactivity of such cells is prevented
by a mechanism termed “licensing” or “disarming”: if an NK cell
does not encounter a ligand for at least one inhibitory receptor
during its maturation it becomes hyporesponsive toward targets
with low or no MHC I (reviewed in [56]). In mouse models, NK
cell responsiveness increases with each inhibitory receptor that
can find its ligand during maturation [12, 57]. The tuning of NK
cell responsiveness is not restricted only to the maturation stages,
rather it’s a continuous process depending on the availability of
receptor ligands. Unlicensed cells are not redundant; the inflam-
matory environment can ameliorate their anergy and they can be
effective against targets that express self-MHC I that would inhibit
licensed cells, such as MHC I-expressing tumors or viruses such
as CMV that encode NK cell inhibitory receptor decoys (reviewed
in [12, 57]). Conversely, NK cells in mice that overexpress or con-
stitutively express ligands for NKG2D or Ly49H receptor displayed
tolerance against targets expressing these ligands [12, 58].
NK cell education can also be mediated by non-MHC I self-
molecules [59]. For example, the SFR that have been shown to act
as both inhibitory and activating receptors depending on adaptor
molecules [60], can play a significant role in tuning of NK cell
responsiveness although it is not yet clear whether this tuning
is a consequence of their activating or inhibitory role [61, 62].
MCMV and HCMV regulate the expression of one SFR, 2B4 (Table
1) [63, 64]. It is not known whether other SFRs are targeted by
CMVs however, a recent work demonstrated in mice that SFRs
and their adaptor molecules are promising modulators that can
enhance immune responses to vaccines [65].
Although expression of NK cell receptors is often described
as stochastic, a growing body of research reveals the impact of
inhibitory receptor signaling during NK cell maturation on the
expression of other NK cell receptors [12]. For example, signaling
from activating NK cell receptors via SLP-76 changes the expres-
sion of inhibitory Ly49A, Ly49G2 and Ly49I receptors in mice and
completely abolishes acquisition of KIR2DL1, KIR2DL2/DL3, and
KIR3DL1 in human NK cells and it has been proposed that this
is driven by the expression of activating ligands on bone marrow
stromal cells [66]. Interestingly, cytomegaloviruses have a wide
cell and tissue tropism including bone marrow stromal cells, a
tissue that is important for generation and maintenance of NK
cells, and, in an influenza model, the bone marrow was found
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to be an important site of proliferation of long-lived memory-like
NK cells [67]. It will be interesting to see whether bone marrow
stroma influences the generation of CMV-inducedmemory-like NK
cells and whether latent CMV in the bone marrow modulates NK
cell maturation and education.
Long-term impact of MCMV on NK cell
phenotype, behavior and responses to other
pathogens
Following infection or vaccination, pathogen-specific cells of the
adaptive immune response undergo clonal expansion (prolifer-
ation) and differentiation followed by contraction of the effec-
tor cell pool and formation of long-lived, highly antigen-specific
memory cells with the ability to mount fast and efficient recall
responses. While most NK cell receptors are not antigen specific,
in certain mouse strains the activating Ly49H receptor specifi-
cally recognizes MCMV m157, as described above ( [37, 38]
and reviewed in [68]). However, this pathogen-specific recogni-
tion is restricted only to C57BL/6 and related mice and a few
laboratory strains of MCMV (e.g. most commonly used Smith
and K181 strains) [33, 36, 69–72]. Furthermore, serial passage
of WT MCMV in Ly49H+ mice results in the accumulation of
mutations that abrogate interaction between MCMV and Ly49H
[69, 73], while in mixed infections (infection with 2 or more
strains of MCMV) only MCMV strains that do not engage Ly49H
are able to reach the salivary gland, the main dissemination place
[74].
Nonetheless, Ly49H and m157 interaction results in the
antigen-specific expansion of Ly49H+ cells, control of the virus and
generation of long-lived memory-like NK cells with capabilities
similar to memory T cells (Fig. 1A) and is currently a major model
for studying virus-induced memory NK cell formation. MCMV-
induced memory-like NK cells are less reliant on STAT1- and
STAT4-mediated signals and produce less IFN-γ in response to IL-
12 with IL-18 compared to na¨ıve or Ly49H− NK cells [75]. These
cells also display inappropriate NK cell homing to infected tissues
following adoptive transfer and reduced IFN-γ production during
subsequent influenza or listeria infections, whilst still generating
appropriate responses to MCMV m157+ [75]. It appears, there-
fore, that expansion of CMV-specific memory-like NK cells could
compromise responses to other infections, however this may be
offset by increased responsiveness to antibody-mediated signals
(ADCC) (see below).
HCMV infection leads to accumulation of
terminally differentiated NK cells with
potential long-term consequences
Human CMV infection is characterized by accumulation of highly
differentiated subsets of NK cells (Fig. 1B). Over ten years ago,
Guma et al. observed an expansion of mature (CD56dimCD16−)
NK cells expressing CD94/NKG2C+ in HCMV+ individuals [76].
This observation has now been corroborated in HCMV-infected
children [77], in adults undergoing acute HCMV infection [78]
and in hematopoietic stem cell transplant patients with reacti-
vated HCMV [79, 80], among whom HCMV reactivation is associ-
ated with significantly increased NK cell maturation rates [80–82].
As described above, CD94/NKG2C is an activating receptor for
HLA-E, which is stabilized at the surface of HCMV-infected cells,
suggesting that this is a host protective response to control
HCMV infection and maintain latency. Moreover, many expanded,
CD94/NKG2C+ cells subsequently lose expression of the FcRγ
adaptor molecule [83, 84]. Despite the FcRγ loss, not only is sig-
naling through the Fc-receptor CD16 preserved (due to the ability
of CD16 to transmit signals through CD3ζ) but FcRγ− cells display
enhanced ADCC responses to HSV-1 [85] and influenza-infected
targets [86], as well as against antibody-opsonized HCMV virions
[87], especially if NKp46 [85] or CD2 are also engaged [88, 89].
HCMV-expanded NK cells are long-lived [90, 91] with stable epi-
genetic imprints that are transmitted to the cell progeny and that
resemble those found in memory T cells [86, 92]. CD94/NKG2C+
FcRγ- NK cells are thus highly adapted to combat HCMV re-
infection or reactivation in seropositive individuals, although CMV
infection can also prompt the expansion of NKG2C− NK cell pop-
ulation (discussed below).
Differences are emerging, however, in the phenotype of CMV-
induced memory-like NK cells in humans and mice. Many NK
cells in HCMV+ individuals are deficient in the transcription
factor PLZF, and many of PLZF- cells also lack the SYK, EAT-
2 and FcRγ adapter molecules (Fig. 1B) as a consequence of
hyper-methylation of their promoter regions. Furthermore, epi-
genetic modification (methylation) of the IFN-γ gene promoter
explains increased secretion of this cytokine upon re-stimulation
[93]. Interestingly, although NK cells in HCMV+ patients display
demethylation of PRDM1 and ZBTB32 genes [93] the same genes
that regulate proliferative burst of Ly49H+ memory-like NK cells
in mice [94], mouse memory-like NK cells are FcRγ and Syk suffi-
cient [86]. Stable epigenetic relaxation of cytokine secretion and
regulators of proliferation could be potentially dangerous, espe-
cially in cells that are highly activated by an inflammatory milieu.
In the case of human CD94/NKG2C+ NK cells, this danger is cir-
cumvented by downregulation of receptors for IL-12 and IL-18
[95], common NK cell activating cytokines, and by dampening of
tonic signaling from activating receptors mediated by Syk, EAT-2
and FcRγ [96].
Although HCMV-expanded NK cells display a mature phe-
notype associated with reduced cytokine responsiveness, IFN-γ
cytokine-driven responses of NKG2C+CD57− NK cells in HCMV+
individuals are strongly boosted by vaccination compared to
their CD57bright counterparts consistent with further differentia-
tion steps occurring before these cells lose cytokine responsive-
ness [97]. The extent to which highly differentiated FcRγ−, PLZF−
adaptive NK cells participate in vaccine-induced responses has not
yet been fully addressed and it is conceivable that vaccines or
adjuvants relying heavily on cytokine-driven pathways may be
less potent in HCMV+ individuals with high frequencies of these
cells.
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Figure 1. CMV infection induces long-lived memory-like NK cells in mice and humans. (A) Around half of all NK cells in C57BL/6 mice express
Ly49H. Upon MCMV infection, they proliferate strongly and efficiently control the virus [184], even upon transfer into Ly49H- mouse strains [185].
Following viral clearance, the expanded pool of Ly49H+ cell contracts leaving a small proportion of long lived NK cells (detected up to 70 days PI)
with recall ability reminiscent of memory T cells and with diminished ability to respond to other pathogens or MCMV lacking m157 [74]. Like T
cells, memory-like NK cells require pro-apoptotic Bim-signaling for efficient contraction and memory formation [186], as well as co-stimulation
via other co-stimulatory receptors such as DNAM-1 and Ly49D [114, 187] (not shown). (B) In physiological conditions, two subsets of human NK
cells exist. Functionally competent but immature CD56brightCD16- NK cells that mostly reside in secondary lymphoid organs, express inhibitory
NKG2A, are excellent cytokine producers but poor killers give rise to the fully mature and cytotoxic, major NK cell population in the blood
characterized as CD56dimCD16+NKG2A-/+ inhibitory KIR+ cells [188, 189]. Upon HCMV infection, a new subset appears among the fully mature
CD56dimCD16+ population that is characterized by increased levels of NKG2C compared to NKG2C+ cells in HCMV- patients [77] (although not all
expanded cells are NKG2C+), high levels of LIR-1 and, in many cases, CD57 (marker of fully mature cells) [77], perforin and granzyme expression,
and the increased ability to secrete IFN-γ and TNFα. These cells often express at least one inhibitory self-binding KIR that allows licensing of these
cells [80, 95, 107, 190]. Expanded NKG2C+ NK cells in HCMV+ TAP-deficient patients express polyclonal KIRs and are unresponsive toward HLA I
negative targets [191]. Furthermore, most of these cells are deficient for adaptor molecule FcRγ and, consequently, express lower levels of those
receptors that depend on FcRγ for signal transmission such as NKp30 and NKp46 [82, 84, 86], while there are no changes in the expression of
DNAM-1 and 2B4. Some also lose signaling molecules SYK and EAT-2 [92].
The molecular mechanisms behind expansion of the
CD94/NKG2C+ subset of NK cells are not yet completely
clear. Although CD94/NKG2C+ NK cells expand only in HCMV
infected individuals [98], the rate and extent of the expansion
varies greatly among HCMV+ individuals (reviewed in [99]).
CD94/NKG2C+ NK cells can expand in vitro when co-cultivated
with fibroblasts undergoing productive HCMV replication. HLA
Class I regulators encoded by the US2-11 gene region are required
for this expansion but, despite the demonstration of weak inter-
actions between NKG2C and UL18 [100, 101] neither UL16 nor
UL18 are required. Interaction of NKG2C with HLA-E, and IL-12
secretion by monocytes, has also been identified as prerequisites
for the expansion of NK cells in this context [102]. The proportion
of CD94/NKG2C+ NK cells increases with age in different popula-
tions and surface levels of NKG2C correlate with the copy number
of KLRC2, the gene encoding NKG2C [84, 103–105]. Among con-
genitally infected children, symptomatic HCMV infectionwas asso-
ciated with higher proportions of CD94/NKG2C+ NK cells [105],
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suggesting that their expansion is ligand-driven. Among African
children, anti-HCMV antibody titres were higher in KLRC2−
heterozygous and homozygous null individuals than in homozy-
gous KLRC2+ children suggesting that lack of KLRC2 impairs con-
trol of the virus [104], but this was not seen in adults in the
same community or in congenitally infected children [105]. A
recent finding showing earlier accumulation of effector memory
CD45RA+ CD8 T cells in KLRC2−/− individuals provides a possible
explanation for this discrepancy [88].
The CD94/NKG2C+ NK cell population is not the only NK
cell population that proliferates in response to HCMV infec-
tion. CD57hiNKG2A−NKG2C− expanded populations have been
observed in both NKG2C sufficient and deficient subjects; a recent
study identified expansion of FcRγ–LIR-1+ cells in both NKG2C+
and NKG2C− NK cell populations among CMV+ renal trans-
plant patients, irrespective of their KLRC2 genotype, although the
FcRγ–LIR-1+ NKG2C− cells displayed greater ADCC against anti-
CMV antibody-coated targets than did the FcRγ–LIR-1+ NKG2C+
population [106]. A recent report analyzing expansion of NK cells
against HCMV-infected targets in vitro demonstrated expansion
of NK cells independently of NKG2C expression [107]. It is not
yet clear what drives the expansion of these CD94/NKG2C- NK
cells. Although it was originally associated with the presence of
activating KIR receptors of KIR B haplotype [108, 109], a later
study found no difference between overall frequencies of acti-
vating KIRs between NKG2C- and NKG2C+ memory-like NK cells
[88]. Both NKG2C- and NKG2C+ memory-like NK cells showed
enhanced ADCC responses, higher levels of DNAM-1 and CD2 and
demethylation of the IFNG promoter but were poorly responsive
to IL12/IL18 and expressed lower levels of NKp46 [88].
Cytokine-induced memory-like NK cells
in CMV infection and vaccination
In addition to CMV-induced memory-like NK cells, cytokine-
induced memory-like NK cells (CIML) have been reported in mice
and in humans [110]. Pre-activation of mouse NK cells with a
cocktail of IL-12, IL-18 and low dose IL-15 gave rise to cells that
secreted increased levels of IFN-γ following activation through
activating receptor engagement or following cytokine-stimulation
up to 3 weeks later [111]. The strength of the subsequent response
depended on the duration of pre-activation and enhanced respon-
siveness was maintained after homeostatic proliferation, indicat-
ing heritable epigenetic modification [112]. However, in contrast
to virus-inducedmemory-like NK cells, CIML NK cells did not show
enhanced cytotoxicity and enhanced cytokine production was lost
by week 12. The upregulation of IL-2R (CD25) plays a key role in
the maintenance of human CIMLs which mount strong secondary
responses in presence of picomolar concentrations of IL-2 [113].
Murine CIML also rely on common-γ chain cytokine signaling for
their long term maintenance [112]. Similar observations have
been made for human NK cells pretreated in vitro with various
combinations of IL-12, IL-15 and IL-18 [114] (Fig. 2) and it is thus
feasible that the inflammatory environment associated with acute
viral infection, including CMV infection, may contribute to the for-
mation of memory-like NK cells in vivo in humans and in mice.
Indeed, induction of long-lived CIMLs in parallel with Ly49H+
memory-like NK cells has recently been reported in mice [115]
and another study has shown that IL-12 (but not Ly49H-m157) is
required for induction of IL-2R during MCMV infection [116]. In
the context of tumors, however, CIMLs are generated to a much
lower extent and their responses—against the tumor itself or after
engagement of NK1.1 or NKG2D ligands—are much weaker than
those of MCMV-induced Ly49H+ memory-like NKs [115]. How-
ever, when transferred into the MCMV-free environment, CIMLs
showed better survival and persistence than their virally induced
counterparts.
This recent appreciation of the possibility of enhancing or mod-
ifying NK cell responsiveness by pre-activation with cytokines or
exposure to viruses, opens up the potential for new prophylac-
tic and therapeutic interventions (designed to generate memory-
like NK cells) for combatting infection or malignancy (Fig. 2).
In humans, in vitro stimulation of peripheral blood mononuclear
cells (PBMC) with vaccine antigens leads to the bystander acti-
vation of NK cells in individuals naturally exposed to, or pre-
viously vaccinated against, the corresponding pathogens (Fig.
2, [95, 117, 118]). Active vaccination (with rabies, malaria RTS,S,
influenza TIV and LAIV, BCG and therapeutic HIV gp120 vac-
cines) has been shown to induce vaccine antigen-specific CD4+
T cell and IL-2 dependent NK cell responses to the vaccinat-
ing antigens (Table 2) [119–124]. As for CIMLs, cell surface
expression of CD25, forming the high affinity interleukin-2 recep-
tor (IL-2R) and thereby increasing sensitivity to antigen-induced
IL-2, has been shown to be an important feature of vaccine-
induced NK cell responses [119, 122, 123, 125, 126]. Whole
organism vaccines including influenza, yellow fever, BCG and
DTPiP (which encode pathogen associated molecular patterns,
PAMPS) are potent inducers of myeloid cell-derived IL-12 and
type I interferons which not only synergise with IL-2 to activate
NK cells after vaccination [119, 122, 124] but also induce CIMLs
[97, 119, 124, 127]. In sharp contrast to CMV infection, however,
vaccination and cytokine-mediated pre-activation lead to a tempo-
rary expansion (or redistribution) of less differentiated CD56bright
and CD57- CD56dim NK cell subsets [97, 119, 124, 125, 127]
but these eventually revert to pre-vaccination levels. For example,
the elevated cytokine driven response observed after influenza
or yellow fever 17D vaccination of Europeans persisted for up 3
months [104, 127], the response to influenza or DTPiP vaccina-
tion of Gambians lasted for up to 6 months and the response
to BCG vaccination in South Africans lasted for up to 1 year
[97, 124].
Broader effects of HCMV exposure on
vaccination outcomes
A broader influence of HCMV infection on vaccine induced immu-
nity has been inferred from several studies comparing naturally
occurring or vaccine-induced antibody levels or T cell responses
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Figure 2. Human cytokine-induced memory-like
NK cells. Human NK cells can differentiate into
CIMLs following in vitro treatment with cytokines
or after vaccination. In vitro, both CD56bright and
CD56dim cells can give rise to CIMLs. CD56bright
CIMLs showagreater capacity to produce IFN-γ and
fail to differentiate into CD56dimNK cells. Unlike
virus-inducedmemory-like NK cells, humanCIMLs
are characterized by lack of CD57 and increased
surface expression of NKG2A, CD94, NKp46 and
CD69, which correlate with their ability to secrete
IFN-γ. CIMLs that develop after vaccination are
similar to in vitro generated cells in terms of
increased IFN-γ secretion, enrichment for CD57-
cells and induction of IL-2R [118, 121, 122, 124, 125].
against distinct pathogens in HCMV+ to HCMV- individuals. For
anti-influenza responses, the impact of HCMV infection can be
positive or negative depending on age and the immune readout.
Poor overall health indicators have been associated with higher
HCMV antibody titres, higher NK cell frequencies and lower B cell
frequencies in the elderly [128] and inverse correlations have
been reported between anti-HCMV IgG titres and vaccination-
induced antibodies to influenza in the elderly [128] and in healthy
young adults [129, 130]. Other studies have demonstrated either
higher [131] or lower [132] antibody responses to influenza vac-
cination in HCMV- compared to HCMV+ young adults, suggest-
ing that the duration of HCMV infection (acute versus longstand-
ing) may affect the response to vaccination. In support of this
hypothesis, young mice with recently established MCMV infec-
tion displayed better IFN-γ−dependent control of influenza infec-
tion and increased frequencies of influenza antigen-specific CD8+
T cells compared to older mice with chronic, latent MCMV infec-
tion [132]. If confirmed in larger studies, CMV-induced enhance-
ment of anti-viral immunity in the recently infected may confer a
survival advantage in early or mid-life but CMV-mediated immune
senescence would reduce longevity in later life. This dynamic
might therefore prove beneficial to children in many low-income
countries with extremely high HCMV seroprevalence despite evi-
dence of potentially deleterious effects in older populations in
industrial nations [26, 104, 133–135].
The impact of HCMV infection on NK cell
responses to vaccine antigens
The impact of HCMV infection on vaccine antigen or cytokine-
driven response pathways can be profound. In vitro NK cell IFN-
γ responses to several previously encountered vaccine antigens,
including Influenza, whole cell pertussis and DTPiP (alone or
co-stimulated with low concentrations of IL-12 and IL-18) are
impaired in HCMV+ individuals [95, 97, 119]. This effect is con-
sistent with the well-documented impairment of NK cell IFN-γ
and CD25 responses to exogenous cytokines among HCMV+ indi-
viduals [95, 118, 119, 136, 137], and suggests that HCMV infec-
tion impairs the NK cell response to vaccine antigen-induced IL-
2 [95, 119]. As demonstrated for CIML, post-vaccination, NK cells
appear to be reliant on cytokine-driven induction of CD25 for
their maintenance and function, raising the possibility that pro-
duction of, or responses to, the costimulatory cytokines (type I
IFNs, IL-12 or IL-18) that are required for CD25 induction may
be reduced in HCMV+ individuals [113, 119]. This is consistent
with the impaired NK cell responses of HCMV+ individuals reflect-
ing, in part, their low frequencies of less-differentiated CD56bright
and CD56dimCD57- NK cells, which are intrinsically more cytokine
responsive [95, 119]. However, chronic HCMV infection reduces
the cytokine responsiveness of all NK cell subsets [95, 119], indi-
cating that HCMV infection has much broader effects on NK cells,
C© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
58 Martin R. Goodier et al. Eur. J. Immunol. 2018. 48: 50–65
Table 2. NK cell responses after active vaccination and accessory cytokine requirements
Vaccine Composition/adjuvant NK cell response Accessory
cytokine
requirement or
association
References
BCG (Bacillus Calmette–Gue´rin) Attenuated whole organism IFN-γ IL-2, IL-12, IL-18 [124]
BCG Attenuated whole organism IFN-γ (ex-vivo) [183]
HIV Therapeutic subunit
gp120/nef/tat vaccine
IFN-γ IL-2, IL-12 [123]
Influenza Intramuscular or Intradermal
Trivalent inactivated (TIV) or
Live attenuated (LAIV)
IFN-γ, CD25, CD107a IL-2, IFN-α [119]
Influenza TIV or seasonal infection CD69, CD25 (ex-vivo) [122]
Influenza TIV IFN-γ [184]
Influenza TIV IFN-γ, CD25, CD107a [97]
DTPiP (diphtheria, tetanus,
pertussis, inactivated
poliovirus)
Subunit IFN-γ [97]
Malaria RTS,S Conjugate IFN-γ, CD69, IL-2 [121]
Rabies Inactivated whole organism IFN-γ, CD69 IL-2, IL-12, IL-18 [120]
CD107a, perforin
Yellow Fever Live attenuated whole organism Ki67, CD69 IFN Type I/III [127]
either by affecting their differentiation or licensing or by reducing
the costimulatory capacity of accessory cells.
Remarkably, although vaccination results in limited boosting
of vaccine antigen driven responses, several vaccines boost the
responses to higher concentrations of cytokines predominantly in
HCMV+ individuals where these responses are down-regulated.
Influenza vaccination preferentially boosts IL-12 and IL-18 stimu-
lated NK cell IFN-γ, CD25 and CD107a expression in HCMV+ Euro-
peans, while both TIV (Trivalent Influenza Vaccine) and DTPiP
have this effect in African populations where HCMV infection is
near universal [97, 119]. The similar boosting of NK cell IFN-
γ responses to cytokines after Yellow fever vaccination in Euro-
peans or BCG vaccinated South African populations, although not
explicitly investigated according to HCMV exposure, is also likely
to involve HCMV+ subjects [124]. The boosting of cytokine-driven
responses in all of these studies preferentially expands or activates
less differentiated subpopulations of NK cells.
Receptor-mediated activation and ADCC in
the context of CMV infection and
vaccination
Whilst CMV infection negatively influences vaccine-driven
responses that are reliant on accessory cytokines, NK cell acti-
vation via other pathways can also be adversely affected by CMV
infection. For example, murine Ly49H+ ‘memory-like’ NK cells
rely on co-stimulation via DNAM-1 and its induced ligands on
macrophages and dendritic cells [138]; CMV-mediated down reg-
ulation of these ligands may have consequences for responses to
infection or vaccination. Similarly, in humans, reduced expression
of NKp46, and reduced NKp46 signalling capacity in adaptively
expanded NK cells in HCMV+ individuals [92, 136, 137], could
compromise responses to influenza virus by inhibiting the costimu-
latory interaction between NKp46 and viral haemaglutinin [139].
Moreover, US12-mediated down regulation of B7-H6 (a key lig-
and for NKp30) on HCMV-infected fibroblasts can lead to reduced
NK cell degranulation [140]. However, CD94/NKG2C+ NK cells
show enhanced cytotoxic activity against a range of tumour cell
lines which vary greatly in their expression of HLA-E, indicating
that there may be conserved expression of receptors for other acti-
vating ligands [141]. Indeed, HCMV-expanded NK cells rely on
signalling via accessory receptors including CD2 and its ligand,
CD58, on accessory cells [88, 89]. On the other hand, HCMV-
expanded, “adaptive”, CD94/NKG2C+CD57+NK cells express high
levels of CD16, signal very effectively via CD3ζ and possess epige-
netic modifications leading to enhanced receptor-mediated cyto-
toxicity and IFN-γ production [92, 93]. Together these modifica-
tions lead to greatly enhanced capacity for CD16-mediated ADCC,
which may compensate for their loss of cytokine responsiveness
[83, 86, 87, 92]. Interestingly, HCMV-expanded memory-like NK
cells do not appear to target autologous CD4+ T cells [96], a reg-
ulatory feature of NK cells described in murine models of virus-
induced immune responses [142]. Such preservation of pathogen
or vaccine-specific CD4+ T cells is likely to be important for the
maintenance of both vaccine induced CIML and HCMV-associated,
adaptive NK cell expansions.
Conclusion
Although it is clear that cytomegaloviruses are major drivers of cel-
lular immune differentiation, affecting NK cells as well as T cells,
the full impact of CMV on infection, vaccination and healthy life
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span is still unclear. In the case of NK cells, the gradual differenti-
ation away from cytokine-dependent signalling pathways towards
antibody dependent or other receptor-mediated responses could
be beneficial in the long-run, with cytokine-dependent activa-
tion on primary exposure to any given pathogen giving way to
antibody-mediated activation during subsequent infections. The
timing of HCMV infection, and the rate of subsequent cytokine-
driven expansion of “adaptive” NK cells, together with host genetic
background, will determine the relative costs and benefits of this
process. Whilst CMV immune evasins may have evolved to pro-
mote persistence of virus in the host, further research is needed to
establish which of the affected pathways are critical for immune
defence against other pathogens. One as yet unconsidered aspect
of this interaction between CMV and the cellular immune system
is the potential use of CMVs as vaccine vectors [143–149]. CMV
can induce long-term expansion of antigen-specific CD8 T cell
clones, which could be highly beneficial in a vaccine. Simultane-
ous deletion of the NK cell imunoevasins has proven to be a good
strategy for virus attenuation without compromising CD8 T cell
responses. The concurrent potential of CMV-vectored vaccines to
mature NK cells toward potent antibody-dependent effector cells
should however also be explored.
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